Lilly(US:LLY) Prnewswire·2025-11-05 10:00Core Insights - Ailux, a subsidiary of XtalPi, has entered a strategic collaboration with Eli Lilly to enhance the discovery and development of bispecific antibodies for various diseases [1][3]. Group 1: Collaboration Details - The collaboration allows Lilly to utilize Ailux's AI-powered bispecific antibody engineering platform, which combines advanced structural modeling, generative design, and developability analytics [2]. - Under the agreement, Lilly can nominate an undisclosed number of target pairs for bispecific antibody design and may obtain a license for Ailux's platform for internal use [3]. - The deal includes upfront and near-term payments totaling a double-digit million-dollar amount, with a total potential value of up to $345 million, covering development, regulatory, and commercial milestones [3]. Group 2: Company Background - Ailux focuses on developing advanced biotherapeutics using AI-powered solutions and integrates proprietary computational models with wet lab capabilities to address previously undruggable targets [5]. - XtalPi, founded by MIT physicists, leverages quantum physics, AI, and robotics to provide innovative R&D solutions across various industries, including pharmaceuticals [6].